ArticleCancer2015
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.
Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Potential of Mushroom Extracts to Improve Chemotherapy Efficacy in Cancer Cells: A Systematic Review.Cells · 2024Pooled it
- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.Current oncology reports · 2023Pooled it
- Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.BJU international · 2016Pooled it
- A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer.PloS one · 2016Pooled it
- Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.Cancer science · 2017Trial
- Review
- Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.Nutrition & metabolism · 2026Review
- Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine.Nanomedicine (London, England) · 2025Review
- Comparative study on the therapeutic potential of aqueous extracts from commercially cultivated Agaricus bisporus and Lentinula edodes in Sri Lanka: antioxidant, anticancer, antidiabetic, and antibacterial properties.BMC complementary medicine and therapies · 2025Article
- Immunoregulation in Fungal Infections: A Review and Update on the Critical Role of Myeloid-Derived Suppressor Cells.Journal of fungi (Basel, Switzerland) · 2025Review
- Dietary impacts on prostate cancer immunotherapy.Immunotherapy · 2025Review
- Current Advances in the Use of Mushrooms as Therapeutics for Lung Cancer: A Review.Molecules (Basel, Switzerland) · 2025Review
- Harnessing myeloid cells in cancer.Molecular cancer · 2025Review
- Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.Clinical and translational medicine · 2024Article
- Review
- Article
- Review
- Chemical screening identifies the anticancer properties ofJournal of Cancer · 2023Article
- Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota.Frontiers in oncology · 2023Review
- Chemical screening identifies the anticancer properties ofJournal of Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEach year in the United States, nearly 50,000 prostate cancer patients exhibit a rise in prostate-specific antigen (PSA) levels, which can indicate disease recurrence. For patients with biochemically recurrent prostate cancer, we evaluated the effects of white button mushroom (WBM) powder on serum PSA levels and determined the tolerability and biological activity of WBM.
methodsPatients with continuously rising PSA levels were enrolled in the study. Dose escalation was conducted in cohorts of 6; this ensured that no more than 1 patient per cohort experienced dose-limiting toxicity (DLT). The primary objective was to evaluate treatment feasibility and associated toxicity. The secondary objectives were to determine WBM's effect on serum PSA/androgen levels; myeloid-derived suppressor cells (MDSCs); and cytokine levels.
resultsThirty-six patients were treated; no DLTs were encountered. The overall PSA response rate was 11%. Two patients receiving 8 and 14 g/d demonstrated complete response (CR): their PSA declined to undetectable levels that continued for 49 and 30 months. Two patients who received 8 and 12 g/d experienced partial response (PR). After 3 months of therapy, 13 (36%) patients experienced some PSA decrease below baseline. Patients with CR and PR demonstrated higher levels of baseline interleukin-15 than nonresponders; for this group, we observed therapy-associated declines in MDSCs.
conclusionsTherapy with WBM appears to both impact PSA levels and modulate the biology of biochemically recurrent prostate cancer by decreasing immunosuppressive factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.